Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2022 Dec 23;26(1):194–200. doi: 10.1038/s41391-022-00636-0

Figure 4:

Figure 4:

Associations between clinical outcomes and baseline PSA values. (A) Baseline PSA value is significantly higher in those achieving a PSA50 response anytime on study (i.e. responders vs. non-responders). The median baseline PSA in responders vs. non-responders was 43 vs. 16 ng/mL (P=0.03), respectively. (B) Baseline PSA value at or above vs. below the median PSA (22.3 ng/mL) is weakly associated with clinical/radiographic PFS.